Financial relationships between board-certified neurologists and the pharmaceutical industry in Japan

Keywords

conflicts of interest / ethics / health policy / physician payment / profession / professionalism

References

[1] RosenbaumL. Conflicts of interest: part 1: reconnecting the dots–reinterpreting industry-physician relations. N Engl J Med. 2015;372(19):1860-1864.

[2] DrazenJM. Revisiting the commercial-academic interface. N Engl J Med. 2015;372(19):1853-1854.

[3] AhlawatA, Narayanaswami P. Financial relationships between neurologists and industry: the 2015 open payments database. Neurology. 2019;92(21):1006-1013.

[4] TringaleKR, Marshall D, MackeyTK, ConnorM, MurphyJD, Hattangadi-GluthJA. Types and distribution of payments from industry to physicians in 2015. JAMA. 2017;317(17):1774-1784.

[5] MarshallDC, TarrasES, RosenzweigK, Korenstein D, ChimonasS. Trends in industry payments to physicians in the United States from 2014 to 2018. JAMA. 2020;324(17):1785-1788.

[6] MurayamaA. Industry-sponsored meal payments are associated with prescriptions and medicare expenditures on brand-name colchicine in the United States. Int J Rheum Dis. 2023.

[7] MurayamaA. Pharmaceutical industry-sponsored meals and prescriptions of biologics for asthma. J Allergy Clin Immunol Pract. 2023;11(9):2916-2918.

[8] LoderE, Brizzell C, GodleeF. Revisiting the commercial-academic interface in medical journals. BMJ. 2015;350:h2957.

[9] SteinbrookR. Guidance for guidelines. N Engl J Med. 2007;356(4):331-333.

[10] MurayamaA, HoshiM, SaitoH, et al. Nature and trends in personal payments made to the respiratory physicians by pharmaceutical companies in Japan between 2016 and 2019. Respiration. 2022;101(12):1088-1098.

[11] KusumiE, Murayama A, KamamotoS, et al. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer J. 2022;12(4):54.

[12] MurayamaA, SaitoH, KamamotoS, et al. Evaluation of non-research payments from pharmaceutical companies to urologists in Japan between 2016 and 2019. Int Urogynecol J. 2023;34(6):1285-1292.

[13] MurayamaA, MamadaH, ShigetaH, et al. Financial relationships between pharmaceutical companies and rheumatologists in Japan between 2016 and 2019. J Clin Rheumatol. 2023;29(3):118-125.

[14] MurayamaA, Kamamoto S, SaitoH, OzakiA. Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Sci Rep. 2023;13(1):7425.

[15] MurayamaA, Kamamoto S, KawashimaM, et al. Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019. BMJ Open. 2023;13(4):e068237.

[16] IkedaS, MimuraM, IkedaM, et al. Economic burden of Alzheimer's disease dementia in Japan. J Alzheimers Dis. 2021;81(1):309-319.

[17] ShimadaY, OzakiA, SaitoH, Sawano T, TanimotoT. Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016. Alzheimers Dement (N Y). 2019;5:228-230.

[18] MurayamaA. Evaluation of research and non-research industry payments to endocrinologists in the United States: an analysis of the open payments database from 2014 to 2022. Diabet Med. 2023:e15253.

[19] MurayamaA. Nine-year analysis of industry payments to geriatricians in the United States between 2014 and 2022. J Am Med Dir Assoc. 2023.

[20] MurayamaA, KugoH, SaitoY, Saito H, TanimotoT, OzakiA. A 9-year investigation of healthcare industry payments to pulmonologists in the United States. Ann Am Thorac Soc. 2023;20(9):1283-1292.

[21] MurayamaA, Kamamoto S, KugoH, SaitoH, OzakiA. Research and nonresearch industry payments to nephrologists in the United States between 2014 and 2021. J Am Soc Nephrol. 2023;34(10):1709-1720.

[22] InoueK, Figueroa JF, KondoN, TsugawaY. Changes in industry marketing payments to physicians during the covid-19 pandemic: quasi experimental, difference-in-difference study. BMJ Med. 2022;1(1):e000219.

[23] KhunteM, ZhongA, LeeC, WuX, GandhiD, Malhotra A. Industry payments to physicians in the United States from 2017 to 2021 and the impact of the COVID-19 pandemic. Mayo Clinic Proc. 2024.

[24] Santamaria-BarriaJA, Nelson H, JiangH, et al. Open payments data analysis of general and fellowship-trained surgeons receiving industry general payments from 2016 to 2020: payment disparities and COVID-19 pandemic impact. Ann Surg. 2023;278:396–407.

[25] MurayamaA, Kamamoto S, SaitoH, et al. Pharmaceutical payments to Japanese board-certified infectious disease specialists: a four-year retrospective analysis of payments from 92 pharmaceutical companies between 2016 and 2019. Int J Environ Res Public Health. 2022;19(12):7417.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.